Pfizer said it would stop studying the pill after a participant in one of its trials experienced a drug-induced liver injury.

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Impact on Drug Development Process The standards for drug impurities influence drug safety and effectiveness while simultaneously affecting all stages of drug development. Key aspects include: R&D ...

Till date, over 280 antibody drug conjugates have been either approved or being investigated in clinical studies, whereas more than 250 candidates are in the early stages of development.

For pharma R&D, the expected ROI was 5.9% in 2024, up from 2023’s 4.1%. Of note is the role that GLP-1 therapies played in that increase, with the average return dropping to 3.8% when the drug ...